Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Mireia Uribe‐Herranz; Aina Oliver‐Caldés; Neus Martínez-Micaelo; Marta Español‐Rego; Maria Val-Casals; Roberto Martínez-Soler; Elisa Rubio-García; Valeria Brunello; Erik Z. Mihelic; Nela Klein-González; Daniel Benítez‐Ribas; Núria Amigó; Andrea Vergara; Valentín Ortiz‐Maldonado; Luis Gerardo Rodríguez‐Lobato; Julio Delgado; Iñaki Ortiz de Landazuri; Verónica González‐Calle; Valentín Cabañas; Beatriz Martín-Antonio; Lorena Pérez-Amill; Juan Luis Reguera; Paula Rodríguez‐Otero; Bruno Paiva; Joaquín Martínez‐López; María‐Victoria Mateos; Mariona Pascal; Álvaro Urbano‐Ispizua; Europa Azucena González‐Navarro; Carlos Fernández de Larrea; Manel Juan

doi:10.1158/2643-3230.30040930

September 3, 2025Open Access

Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

View Full Paper

Ask AI

Bookmark

Share

Key Points

Gut microbiota composition is linked to the effectiveness of CAR T-cell therapy in myeloma patients, highlighting a potential biomarker.
Taxonomic profiles of the gut microbiota were assessed in multiple myeloma patients before CAR T infusion, showing significant variation.
Analysis of gut microbiota before lymphodepletion suggests its role in shaping metabolic and immune responses during therapy.
Further investigation into microbiota may inform treatment strategies and improve efficacy of CAR T-cell therapy in myeloma.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Observational analysis reveals microbiota influence on outcomes in myeloma patients receiving CAR T-cell therapy.

Abstract

Supplementary Figure S1 displays the gut microbiota's phylum and class-level taxonomic profiles in multiple myeloma patients prior to CAR T-cell infusion, comparing samples taken at apheresis and before lymphodepletion.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Uribe‐Herranz et al. (2025) studied this question.

synapsesocial.com/papers/68c189ca9b7b07f3a0612e5f https://doi.org/10.1158/2643-3230.30040930

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure 1 from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading